Merck & Company
West Coast Innovation Hub
499 Illinois St. Suite 100
About Merck & Company
Meet representatives from Merck and connect with your Life Science peers at our 2018 Biotech Bay and Genetown Fall Talent Connect. Learn more about Merck here.
Merck and Co., Inc. is a global research-driven pharmaceutical company dedicated to putting patients first. Merck discovers, develops, manufactures, and markets vaccines and medicines in over 20 therapeutic categories directly and through its joint ventures. Our mission is to provide society with superior products and services by developing innovations and solutions that improve the quality of life. The focus of research at Merck is on innovation in all areas of drug research and development, working on programs to satisfy unmet medical needs.
With approximately 60,000 employees, Merck conducts research at ten major research centers in the United States, Europe, and Japan, manufactures products in 30 facilities, and sells products in approximately 150 countries.
At Merck, our strategy for growth is based on breakthrough research - both internal and external through partnerships - and demonstrating the value of our medicines to patients, payers, and providers. Worldwide sales in 2004 were $22.9 billion. Merck continues to invest heavily in research and development, with R&D spending in 2005 estimated to be approximately $4 billion.
Merck's product line includes a broad portfolio of highly innovative prescription products in important therapeutic areas. Human health products include medicines to treat high blood pressure, congestive heart failure, elevated cholesterol levels, osteoporosis, benign prostatic hypertrophy, arthritis, pain, migraine, glaucoma, gastrointestinal ulcers, infectious diseases (antibiotic, anti-fungal, and antiviral agents), and vaccines to prevent childhood diseases and hepatitis A and B.
At Merck, we are strongly committed to partnership success. We have a long tradition of successful partnerships. Alliances with innovative partners are an integral part of our long-term business and research strategy. More than one-third of our sales are from alliance products and patents, including some of our biggest growth drivers.
Our vision is to create a "virtual lab" - the pursuit of the best scientific programs from both internal research and external collaborations. This approach will accelerate the successful development and commercialization of breakthrough discoveries that can bring meaningful improvements to patients' lives.
Our focus is seeking alliances for new NCE's and biological entities as product candidates for development. We are open to basic research collaborations and early research technologies as well.
Merck welcomes partnerships touching virtually all human health therapeutic areas that address unmet needs for patients, as well as technologies that will enhance the productivity of our research laboratories. Therapeutic areas of particular interest include cancer, central nervous system disorders, diabetes, and obesity. Also of interest include the following: anti-infectives, anti-virals, cardiovascular diseases, gastrointestinal diseases, immunology, new vaccine technology, ophthalmics, osteoporosis, pain, respiratory, vaccines, and platform research technology.
To contact Merck about a licensing opportunity, please contact Chief Licensing Officer, Merck & Co., Inc., One Merck Drive, P.O. Box 100, Whitehouse Station, NJ 08889 USA; Fax: 908-735-1201. Please provide a brief, non-confidential overview of your discovery with sufficient data to allow a preliminary scientific review.
For further information, please visit our website at http://www.merck.com/licensing/
300 articles with Merck & Company
Multiple biotech companies are scheduled to release their quarterly reports next week. BioSpace takes a quick look at some these companies and the announcements they have made through 3Q2018.
Merck’s KEYTRUDA® (pembrolizumab) in Combination with Pfizer’s Inlyta® (axitinib) Significantly Improved Overall Survival (OS) and Progression-free Survival (PFS) as First-Line Therapy for Advanced or Metastatic Renal Cell Carcinoma
KEYTRUDA is First Anti-PD-1 Therapy in Combination to Improve Both OS and PFS in Advanced or Metastatic RCC, the Most Common Type of Kidney Cancer
Merck today announced the appointment of Jim Scholefield as chief information and digital officer, effective Oct. 29, 2018.
Fourth Orphan Drug Designation in the U.S. for AstraZeneca and Merck’s LYNPARZA
eFFECTOR Therapeutics Announces Clinical Collaboration with Merck to Conduct a Phase 2 Combination Trial to Evaluate eFFECTOR's Tomivosertib (eFT508) with KEYTRUDA® (pembrolizumab) for Metastatic Triple Negative Breast Cancer
eFFECTOR Therapeutics, Inc. today announced it has entered into a clinical collaboration agreement with Merck (known as MSD outside the United States and Canada), through a subsidiary, to evaluate the combination of eFFECTOR's tomivosertib (eFT508), an oral, small molecule inhibitor of MNK1/2, with Merck's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), for the treatment of patients with metastatic triple negative breast cancer (TNBC).
10/15/2018Who mixed things up in the biotech world this past week? Pfizer announces its leadership team, Rheos gets a new COO, and board of directors updates from multiple biopharma companies.
Merck will hold its third-quarter 2018 sales and earnings conference call with institutional investors and analysts at 8:00 a.m. EDT on Thursday, Oct. 25.
Real-world evidence and longer clinical trial follow-up show no increased incidence of serious adverse events
Pivotal Phase 3 Data Included in ESMO Presidential Symposium and Official Press Program: KEYTRUDA® (pembrolizumab) as First-
Merck KGaA, Darmstadt, Germany Data at ESMO 2018 Congress Highlight Multiple Therapeutics with Potential to Transform Cancer Care
First presentation of Phase III data for avelumab (plus axitinib) in previously untreated, advanced kidney cancer
In looking at companies that are shaping the future, Time Magazine selected 50 business that are leading the charge. While many tech companies lead the way, there are several pharma and life science companies that are also disrupting the future.
Late-breaking Phase II primary endpoint data for investigational therapy evobrutinib, the first oral BTK inhibitor to show clinical proof-of-concept in RMS
ImmunoGen to Present Initial Data from FORWARD II Expansion Cohort of Mirvetuximab Soravtansine in Combination with KEYTRUDA at ESMO
ImmunoGen, Inc. today announced that initial findings from the FORWARD II expansion cohort of mirvetuximab soravtansine in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), will be presented at the European Society for Medical Oncology (ESMO) Congress from October 19-23, 2018 in Munich, Germany.
Merck’s HIV Therapy DELSTRIGO™ (doravirine / lamivudine / tenofovir disoproxil fumarate) Meets Primary Efficacy Endpoint in Phase 3 DRIVE-SHIFT Study Evaluating Switch to DELSTRIGO from Other Antiretroviral Treatment Regimens
Merck today announced the first presentation of data from the Phase 3 DRIVE-SHIFT trial evaluating a switch of medication to DELSTRIGO™
Merck Announces Week 96 Data from Pivotal Phase 3 DRIVE-AHEAD Study Evaluating DELSTRIGO™ (doravirine / lamivudine / tenofovir disoproxil fumarate) for the Treatment of HIV-1 in Treatment-Naïve Patients
Merck today announced new results from the Phase 3 DRIVE-AHEAD clinical trial evaluating the efficacy and safety of DELSTRIGO™
Medivir AB today announced safety and efficacy data following an interim analysis of phase I data from the ongoing phase I/II study of birinapant in combination with MSD's anti-PD-1 therapy, Keytruda®.
In April, Dr. Robert Redfield, the new head of the CDC, boldly predicted that the AIDS epidemic can be defeated by 2025. This morning Merck, Janssen and Gilead all released clinical data for HIV treatments that could make Redfield’s prediction a reality.
German company Bayer AG is laying off 227 staffers at its manufacturing plant in Berkeley, California. Most of the cuts took place on October 3.
Memorial Sloan Kettering's Chief Executive Officer Craig Thompson has resigned from the boards of directors at Merck and Charles River Labs as the cancer center continues to be scrutinized for its ties to the pharmaceutical industry.
Merck Announces “Safer Childbirth Cities” Initiative, Issues Call to Action to Reverse the Rise in U.S. Maternal Deaths
Merck for Mothers Commits Additional $10M to Support Locally Created Solutions to Improve Maternal Health and Reduce Disparities